210 related articles for article (PubMed ID: 22136714)
1. Mitochondrial targeting topotecan-loaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma.
Yu Y; Wang ZH; Zhang L; Yao HJ; Zhang Y; Li RJ; Ju RJ; Wang XX; Zhou J; Li N; Lu WL
Biomaterials; 2012 Feb; 33(6):1808-20. PubMed ID: 22136714
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells.
Zhang L; Yao HJ; Yu Y; Zhang Y; Li RJ; Ju RJ; Wang XX; Sun MG; Shi JF; Lu WL
Biomaterials; 2012 Jan; 33(2):565-82. PubMed ID: 21983136
[TBL] [Abstract][Full Text] [Related]
3. Targeting therapy with mitosomal daunorubicin plus amlodipine has the potential to circumvent intrinsic resistant breast cancer.
Zhang Y; Li RJ; Ying X; Tian W; Yao HJ; Men Y; Yu Y; Zhang L; Ju RJ; Wang XX; Zhou J; Chen JX; Li N; Lu WL
Mol Pharm; 2011 Feb; 8(1):162-75. PubMed ID: 21062083
[TBL] [Abstract][Full Text] [Related]
4. Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice.
Li X; Lu WL; Liang GW; Ruan GR; Hong HY; Long C; Zhang YT; Liu Y; Wang JC; Zhang X; Zhang Q
Eur J Clin Invest; 2006 Jun; 36(6):409-18. PubMed ID: 16684125
[TBL] [Abstract][Full Text] [Related]
5. The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells.
Wang XX; Li YB; Yao HJ; Ju RJ; Zhang Y; Li RJ; Yu Y; Zhang L; Lu WL
Biomaterials; 2011 Aug; 32(24):5673-87. PubMed ID: 21550109
[TBL] [Abstract][Full Text] [Related]
6. Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways.
Li N; Zhang CX; Wang XX; Zhang L; Ma X; Zhou J; Ju RJ; Li XY; Zhao WY; Lu WL
Biomaterials; 2013 Apr; 34(13):3366-80. PubMed ID: 23410681
[TBL] [Abstract][Full Text] [Related]
7. The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery.
Yao HJ; Ju RJ; Wang XX; Zhang Y; Li RJ; Yu Y; Zhang L; Lu WL
Biomaterials; 2011 Apr; 32(12):3285-302. PubMed ID: 21306774
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of WGA modified daunorubicin anti-resistant liposomes in treatment of drug-resistant MCF-7 breast cancer.
Liu S; Song XL; Wang YH; Wang XM; Xiao Y; Wang X; Cheng L; Li XT
J Drug Target; 2017 Jul; 25(6):541-553. PubMed ID: 28277825
[TBL] [Abstract][Full Text] [Related]
9. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals.
Du J; Lu WL; Ying X; Liu Y; Du P; Tian W; Men Y; Guo J; Zhang Y; Li RJ; Zhou J; Lou JN; Wang JC; Zhang X; Zhang Q
Mol Pharm; 2009; 6(3):905-17. PubMed ID: 19344115
[TBL] [Abstract][Full Text] [Related]
10. The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer.
Zhou J; Zhao WY; Ma X; Ju RJ; Li XY; Li N; Sun MG; Shi JF; Zhang CX; Lu WL
Biomaterials; 2013 May; 34(14):3626-38. PubMed ID: 23422592
[TBL] [Abstract][Full Text] [Related]
11. Loss of E-cadherin in multidrug resistant breast cancer cell line MCF-7/Adr: possible implication in the enhanced invasive ability.
Lu L; Zhou D; Jiang X; Song K; Li K; Ding W
Eur Rev Med Pharmacol Sci; 2012 Sep; 16(9):1271-9. PubMed ID: 23047512
[TBL] [Abstract][Full Text] [Related]
12. A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes.
Liu Y; Lu WL; Guo J; Du J; Li T; Wu JW; Wang GL; Wang JC; Zhang X; Zhang Q
J Control Release; 2008 Jul; 129(1):18-25. PubMed ID: 18466993
[TBL] [Abstract][Full Text] [Related]
13. The use of a tumor metastasis targeting peptide to deliver doxorubicin-containing liposomes to highly metastatic cancer.
Wang Z; Yu Y; Dai W; Lu J; Cui J; Wu H; Yuan L; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
Biomaterials; 2012 Nov; 33(33):8451-60. PubMed ID: 22940213
[TBL] [Abstract][Full Text] [Related]
14. Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response.
Jiang L; Li L; He X; Yi Q; He B; Cao J; Pan W; Gu Z
Biomaterials; 2015 Jun; 52():126-39. PubMed ID: 25818419
[TBL] [Abstract][Full Text] [Related]
15. Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer.
Ju RJ; Li XT; Shi JF; Li XY; Sun MG; Zeng F; Zhou J; Liu L; Zhang CX; Zhao WY; Lu WL
Biomaterials; 2014 Aug; 35(26):7610-21. PubMed ID: 24912818
[TBL] [Abstract][Full Text] [Related]
16. DLJ14, a novel chemo-sensitization agent, enhances therapeutic effects of adriamycin against MCF-7/A cells both in vitro and in vivo.
Zhang P; Zheng BB; Wang HY; Chen JH; Liu XY; Guo XL
J Pharm Pharmacol; 2014 Mar; 66(3):398-407. PubMed ID: 24533823
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of mitochondrial targeting antiresistant epirubicin liposomes in treating resistant leukemia in animals.
Men Y; Wang XX; Li RJ; Zhang Y; Tian W; Yao HJ; Ju RJ; Ying X; Zhou J; Li N; Zhang L; Yu Y; Lu WL
Int J Nanomedicine; 2011; 6():3125-37. PubMed ID: 22163164
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of loss of beta 2-microglobulin expression in drug-resistant breast cancer sublines and its involvement in drug resistance.
Ogretmen B; McCauley MD; Safa AR
Biochemistry; 1998 Aug; 37(33):11679-91. PubMed ID: 9709006
[TBL] [Abstract][Full Text] [Related]
19. Modulation of drug-resistant membrane and apoptosis proteins of breast cancer stem cells by targeting berberine liposomes.
Ma X; Zhou J; Zhang CX; Li XY; Li N; Ju RJ; Shi JF; Sun MG; Zhao WY; Mu LM; Yan Y; Lu WL
Biomaterials; 2013 Jun; 34(18):4452-65. PubMed ID: 23518403
[TBL] [Abstract][Full Text] [Related]
20. Adenovirus-mediated p53 gene therapy reverses resistance of breast cancer cells to adriamycin.
Qi X; Chang Z; Song J; Gao G; Shen Z
Anticancer Drugs; 2011 Jul; 22(6):556-62. PubMed ID: 21637162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
